In a Nature Communications Medicine publication, the Verita proprietary platform detected 96 per cent of stage 1 pancreatic cancers and three-quarters of stage 1 ovarian cancers using isolated exosomes and AI-enabled protein marker analysis
The single in vitro diagnostic test helps inform therapy decisions according to clinical guidelines to enable precision medicine earlier in the disease journey
Guardant360 CDx is a comprehensive genomic profiling test that utilizes blood samples from patients with advanced solid cancers
Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
Twist will leverage C2i’s leadership in whole-genome cancer signatures across solid cancers to generate unique synthetic reference materials for cancer detection validation in labs across the globe
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
The platform’s technology works as a compression algorithm for molecular testing
Cryo-technology helps in early diagnosis and palliative care in later stages of cancer
It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
Expertise in exosomes isolation and characterization will drive innovation in this field
Subscribe To Our Newsletter & Stay Updated
